• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Look­ing to carve away mar­ket share from Gilead, Vi­iV and J&J score pos­i­tive PhI­II da­ta for a month­ly, 2-drug HIV ...

7 years ago
R&D

One more gig: Steven Paul de­cides to ex­tend a 35-year track record with one last shot at a big de­vel­op­ment pro­gram

7 years ago
People
Startups

An ex­o­dus of top Gilead ex­ecs con­tin­ues as new­ly named CMO An­drew Cheng heads for the ex­it

7 years ago
People

Bil­lion­aire-backed Ju­ve­nes­cence spins out an­ti-ag­ing, AI start­up Na­pa Ther­a­peu­tics

7 years ago
Financing
Startups

Gilead los­es key patent claims for So­val­di in Chi­na, open­ing door to ear­li­er gener­ic en­try

7 years ago
China

Acor­da CTO Baty­cky is jump­ing ship to run a biotech; Mo­tif gets a PDU­FA date

7 years ago
News Briefing

Ex-Pfiz­er ex­ec Geno Ger­mano joins nanopar­ti­cle start­up Elu­ci­da On­col­o­gy as CEO

7 years ago
People

Roge­rio Vi­val­di jumps from Biover­a­tiv buy­out to lead­ing Flag­ship-seed­ed Sig­ilon's Holy Grail pur­suit

7 years ago
People

Bio­gen’s big break­through drug Spin­raza runs in­to a bar­ri­er as NICE turns thumbs down on re­im­burse­ment

7 years ago
Pharma

Realm Ther­a­peu­tics shares crater — again — on a failed PhII atopic der­mati­tis study

7 years ago
R&D

CEO in­ter­rupt­ed: No­var­tis chief Narasimhan looks to new ethics czar to clean up af­ter the lin­ger­ing Co­hen mess

7 years ago
People
Pharma

Bay­er tar­gets COPD in a new dis­cov­ery al­liance with Hap­lo­gen, Evotec

7 years ago
R&D
Pharma

Pfiz­er On­col­o­gy los­es its CMO to Al­ler­gan as can­cer ex­ec Charles Hugh-Jones makes a ca­reer leap

7 years ago
People

Af­ter in­sid­er trad­ing scan­dal, US con­gress­man drops cam­paign — but stays on the bal­lot; Jun­shi Bio­sciences ap­plies ...

7 years ago
News Briefing

Mus­tang Bio ven­tures in­to gene ther­a­py, li­cens­ing 'bub­ble boy dis­ease' treat­ment from St. Jude

7 years ago
R&D
Pharma

Ver­tex’s fight club rule: Block new treat­ments to cys­tic fi­bro­sis pa­tients un­til Orkam­bi is re­im­bursed prop­er­ly

7 years ago
Bioregnum
Opinion

FDA drafts guid­ance on seam­less clin­i­cal tri­als for can­cer drug de­vel­op­ers

7 years ago
Pharma

Rac­ing No­var­tis on Eylea ri­val, the FDA trips up Re­gen­eron at the fin­ish line

7 years ago
Pharma

Fresh from haul­ing in GSK’s bud­get-priced gene ther­a­py group, Or­chard har­vests $150M mega-round. Is it time to IPO?

7 years ago
Financing
Cell/Gene Tx

Back to the be­gin­ning: Pfiz­er seeds dis­cov­ery-stage neu­ro start­up Mag­no­lia (af­ter ax­ing its own brain R&D)

7 years ago
Financing
Startups

Once stiff-armed at the FDA, new man­age­ment of­fers Am­i­cus a warm em­brace for Galafold -- priced at $315,000

7 years ago
Pharma

Gung ho: Al­ny­lam lands his­toric FDA OK on patisir­an, revving up the first glob­al roll­out for an RNAi break­through

7 years ago
Pharma

Af­ter mixed pipeline up­dates, Re­genXBio to raise $175M in of­fer­ing; Bio­Elec­tron clos­es $40M to prep late-stage ...

7 years ago
News Briefing

PARP in­hibitors for ALS? Penn re­searchers post promis­ing finds in brain dis­ease

7 years ago
Discovery
First page Previous page 1004100510061007100810091010 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.